Life Science Engineering Consultant
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NOT TRUE, GRANTS STILL AVAILABLE
https://www.michaeljfox.org/research/apply-for-grant.html
THANKS OH...MUCH NEEDED
Nice Post OH!!
I couldn't have said it any funnier...Thanks, Still laughing
Dr.J Please inform us when Gerald answers your technical questions. I am certainly curious as to what AMBS's position would be when a new "Physical Method" for delivery of NTF's emerges to compete with CED. Having an ear to the ground seems to be in Gerald's nature but it would be nice to know where he currently stands on this issue.
As he mentioned in the CC for acquiring LymPro....being vigilant and the right timing is important to success. I hope he's closely monitoring emerging technologies in delivery methods for NTF's
Thank you OH
I too believe it may be related to CUSIP.
DTC review is also prompted when issuers provide notice to the Financial Industry Regulatory Authority (“FINRA”) pursuant to Rule 6490, of name changes, stock splits, dividends, reverse mergers and spin-offs. While FINRA reviews the corporate action prompting the notice under 6490, DTC reviews matters related to the issuer’s shares including the tradability of the securities it holds on deposit.
During this review, DTC may discover (previously undetected) illegal free trading share issuances or other fraudulent activity causing DTC to limit or suspend its services. In these instances, DTC may make referrals to appropriate regulators including the SEC’s Division of Enforcement.
That's fine by me if no one else objects.
I READ NO OBJECTIONS!! EMAIL SENT TO IR.
Polling all AMBS IHUB registrants!!
What do you all think about the following statement
Email to AMBS Investor Relation:
We would very much like to have Dr. Jerry as our IHUB media spokesman fielding some of our CC questions because of his medical background and seasoned knowledge of the AMBS technology
Dr.J you are spot on...thinking that myself. Thank You
Good eye-Jack!
You are correct..it's best to have a good broker and a cash account.
WHY WOULD'NT EVERY SERIOUS INVESTOR IN AMBS CONSIDER IT!!
I feel as you do so but in spite of that I put a 2$ sell on AMBS which I believe will be it's value when it goes to the Big.
Nevertheless as a precaution I have put all my shares on the Sell Block "Good Until Cancelled" for a large price so no one will ever feed on my shares in order to continue shorting practices. It works for me and suggest everyone else should take notice.
I respectfully understand what you're saying but I was just making a point for now. It would certainly help bring attention to the stock and not be the first OTC to transition to the Big this way.
Believe me, if the business is viable(I'm deeply committed to)after transition, the A/S share count is always there for refueling future expansion and does not negatively reflect on the intergrity of the management.
Another scenario: Would increasing the share count now before the PPS approaches .50(assuming JV) make the transition to the big quicker with a R/S as Gerald predicted for 2013.
ParadigmDrift:
I have expressed the issue of Biomarkers(such as Nuropro),which I believe was almost ready for market years back, with MJFF in the past and never received a response from them. This is where politics and possibly personal agendas within an organization may play a role in determining the future of biomarkers for the near or long term. [color=bl][/color]
I believe the latter may be the major reason why investors on the fringes are finally committing based on the last few news releases.
Banyan's conclusion to me simply means that this experiment(assay)was successfully repeated to their satisfaction.
This repeat experiment was the next obvious step in this phase of process development and may help certify this assay as a standard reference or control for on going in-vitro experiments. As a reference it may serve as an important development tool in the next critical phase of in-vivo testing. JMHO
I respectfully disagree based on Banyan's concluding remarks:
In conclusion, we believe that results from this in vitro study should be carefully reviewed and interpreted, but one conclusion is clear, MANF appears to be neuroprotective against both NMDA-mediated necrosis induction and STS-mediated apoptosis induction in vitro. These results are consistent with previously executed experiment and support further testing in an in vivo model to confirm whether these events translate into a more complex organismal system/pre-clinical model. This is certainly an exciting compound that deserves further investigation to identify not only molecular mechanisms of action but also potential clinical applications.
THIS IS A TRUE STATEMENT!! - I HAVE A SCHWAB ACCOUNT AND I WAS TOLD MY SHARES CAN BE BORROWED.
Another one bites the dust....
www.reuters.com/article/2013/03/26/us-phytopharm-parkinsons-idUSBRE92P0DR20130326
WOULD BE NICE TO HEAR FROM DR.J! HE IS USUALLY ENLIGHTNING...
Key Research defines AMBS's future.
I seriously don't think for one minute AMBS management is doing serious research for the fun of it. MANF is the future of PD Therapy.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=644" rel="nofollow" target="_blank" >insert-text-here